Carisma Therapeutics Inc.

CARM

Carisma Therapeutics Inc.

CARM

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2025-10-07Shares Purchased (TTM):0Shares Sold (TTM):176,329

Institutional Sentiment:

As of:2025-12-31Institutional Shares Owned:1,547,384Shares Outstanding:41,788,096Institutional Ownership Pct.:3.70%

Earnings Market Reaction:

Filing Date:2025-11-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	3	2	8	18	27	40	57	78	83	76	63	24
Marketable Securities Current	-	-	-	-	-	-	-	0	11	41	76	28
Restricted Cash Current	-	-	-	-	-	-	-	-	-	-	-	21
Prepaid Expense And Other Assets Current	3	2	3	6	7	10	4	3	3	5	6	3
Assets Of Disposal Group Including Discontinued Op…	0	0	3	-	-	-	-	-	-	-	-	-
Assets Current	6	4	14	24	34	51	61	80	98	122	145	55
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	-	-	-	0
Property Plant And Equipment And Finance Lease Rig…	0	0	0	4	5	7	8	7	7	8	8	0
Other Receivables Net Current	-	-	-	-	-	-	-	-	-	-	-	1
Operating Lease Right Of Use Asset	1	1	2	2	2	2	5	2	2	3	3	5
Restricted Cash Noncurrent	-	-	-	-	-	-	-	-	0	0	0	-
Deferred Finance Costs Noncurrent Net	-	-	-	-	-	-	0	0	0	0	-	4
Assets	7	5	16	30	42	59	74	90	107	133	156	72
Assets Noncurrent
Restricted Cash And Cash Equivalents Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Liabilities And Stockhold…
Liabilities Current
Intangible Assets Net Excluding Goodwill	-	-	-	-	-	-	-	-	-	-	-	0
Accounts Payable Current	6	5	3	2	2	2	2	4	2	2	5	2
Goodwill	-	-	-	-	-	-	-	-	-	-	-	0
Accrued Liabilities Current	1	3	5	7	5	9	5	8	7	10	10	10
Deferred Revenue Current	0	0	0	4	1	1	1	1	1	1	2	2
Prepaid Expense Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Operating Lease Liability Current	0	1	1	1	1	1	2	1	1	2	3	3
Other Assets Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Finance Lease Liability Current	0	0	1	1	1	1	1	1	1	1	1	1
Assets Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Other Liabilities Current	0	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	7	9	10	16	11	16	13	16	13	18	21	20
Deferred Revenue Noncurrent	0	41	41	41	41	41	45	45	45	45	45	45
Operating Lease Liability Noncurrent	1	1	1	1	1	1	3	1	1	1	1	1
Convertible Long Term Notes Payable	-	-	-	-	-	-	-	0	0	0	-	34
Finance Lease Liability Noncurrent	0	0	0	0	0	1	1	0	0	1	1	1
Derivative Liabilities Noncurrent	-	-	-	-	-	-	-	0	0	0	-	6
Other Liabilities Noncurrent	0	0	0	0	1	1	1	1	1	2	2	1
Liabilities Noncurrent
Business Combination Contingent Consideration Liab…	-	-	-	-	-	-	-	-	-	-	-	0
Liabilities	7	51	53	58	53	59	63	63	60	66	70	107
Deferred Income Tax Liabilities Net	-	-	-	-	-	-	-	-	-	-	-	0
Stockholders Equity Inclu…
Liabilities Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Preferred Stock Value	-	0	0	0	0	0	0	0	-	-	-	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Temporary Equity Carrying Amount Including Portion…	-	-	-	-	-	-	-	0	0	0	-	108
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Additional Paid In Capital	279	279	278	278	277	276	275	272	270	269	269	1
Retained Earnings Accumulated Deficit	-280	-325	-315	-306	-288	-275	-264	-245	-224	-203	-183	-158
Stockholders Equity	-1	-46	-37	-28	-11	0	11	27	46	67	86	-143
Liabilities And Stockholders Equity	7	5	16	30	42	59	74	90	107	133	156	72
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-	-	-	0.001
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	-	0	0	0	0	-0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	-	-	-	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	-	-	-	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	-	-	-	0
Minority Interest	-	-	-	-	-	-	-	0	0	0	-	14
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	350	350	350	350	350	350	350	350	350	350	100	350
Common Stock Shares Issued	42	42	42	42	42	42	42	41	40	40	40	2
Shares Outstanding	42	42	42	42	42	42	42	41	40	40	40	2

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	4.36%	116.90%	67.65%	-21.82%	5.38%	-85.24%	16.74%	-3.08%	-8.59%	-	-	-
2024	-11.92%	0.66%	-21.85%	18.76%	12.10%	10.99%	-17.07%	-55.31%	-53.79%	-27.10%	-40.32%	42.29%
2023	12.92%	55.22%	-5.22%	4.72%	-28.67%	-53.63%	-6.62%	10.78%	-18.71%	-21.53%	-35.41%	-51.20%
2022	-	-	-	-	-	-	-	-	-	-71.51%	-63.70%	-59.08%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	0.86	0.48	1.34	1.48	3.23	3.25	4.64	5.06	7.53	6.80	6.73	2.78
Quick Ratio	0.41	0.22	1.06	1.12	2.55	2.58	4.30	4.88	7.27	6.51	6.47	2.64
Working Capital	-942.00K	-4.66M	3.51M	7.77M	23.58M	35.10M	47.81M	64.56M	84.61M	104.23M	123.03M	34.92M
Leverage & Debt
Debt to Equity	-8.56	-1.11	-1.44	-2.09	-4.78	163.83	5.77	2.38	1.31	0.99	0.81	-0.75
Interest Coverage TTM	37.66	-63.17	-42.01	-36.53	-24.05	-23.19	-21.61	-18.15	-13.34	-12.18	-17.15	-17.86
Debt Ratio	1.13	10.18	3.30	1.92	1.26	0.99	0.85	0.70	0.57	0.50	0.45	1.48
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.04	0.06	0.13	0.07	0.30	0.24	0.28
Per Share Metrics
Diluted EPS TTM	0.19	-1.18	-1.22	-1.46	-1.53	-1.75	-1.98	-2.59	-2.59	-1.55	-5.83	-28.77
Free Cash Flow Per Share TTM	-0.54	-0.89	-1.14	-1.45	-1.64	-1.84	-1.93	-2.46	-1.57	-1.31	-5.56	-5.54
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-1,985.21%	-1,154.31%	-834.72%	-560.10%	-115.26%	-150.13%	-129.03%
Net Profit Margin TTM	-	-	-	-	-	-1,894.46%	-1,099.43%	-817.30%	-981.35%	-133.48%	-162.27%	-140.67%
Growth Metrics
Net Revenue Growth (1Y)	-	-100.00%	-100.00%	-100.00%	-100.00%	-91.82%	-83.92%	-75.58%	-83.27%	98.95%	99.28%	63.97%
Net Income Growth (1Y)	-112.61%	-31.89%	-37.49%	-30.39%	-38.84%	16.05%	8.93%	41.90%	654.06%	-267.28%	-269.97%	18,122.02%
EPS Growth (1Y)	-112.54%	-32.29%	-38.74%	-43.71%	-40.76%	12.46%	-65.98%	-90.99%	-59.02%	-928.81%	-127.39%	1,561,077.78%
Valuation Metrics
P/E TTM	1.42	-0.33	-0.26	-0.29	-0.64	-0.87	-1.14	-1.13	-1.63	-5.65	-0.53	-
P/B TTM	-13.21	-0.36	-0.35	-0.62	-3.67	175.41	8.53	3.70	3.68	5.29	0.46	-
P/S TTM	-	-	-	-	-	16.50	12.58	9.24	16.03	7.54	0.86	-
Market Cap	11.45M	16.36M	12.95M	17.36M	40.82M	63.15M	92.93M	98.23M	170.41M	353.06M	39.63M	-
Enterprise Value	8.67M	14.71M	5.85M	377.86K	15.11M	24.57M	38.67M	21.49M	88.25M	278.50M	-21.25M	-
Calculated Values
Free Cash Flow TTM	-22.42M	-37.34M	-47.67M	-60.04M	-68.35M	-76.51M	-79.08M	-82.31M	-63.36M	-52.80M	-71.06M	-11.79M
Net Debt	-2.78M	-1.65M	-7.10M	-16.98M	-25.71M	-38.58M	-54.26M	-76.73M	-82.16M	-74.56M	-60.88M	11.56M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-10-07Sale

Owner: Klichinsky, Michael

Title: Chief Scientific Officer

Shares: 56,982

Price/Share: $0.25

Value: $14,245.50

Shares Owned: -

Relationship: Officer

Ownership: Direct

2025-10-03Sale

Owner: Klichinsky, Michael

Title: Chief Scientific Officer

Shares: 119,347

Price/Share: $0.26

Value: $31,030.22

Shares Owned: -

Relationship: Officer

Ownership: Direct

2023-03-02Sale

Owner: Cannell, Thomas R

Title: President and CEO

Shares: 487,487

Price/Share: $0.59

Value: $287,617.33

Shares Owned: 344,150

Relationship: Director,Officer

Ownership: Direct

2023-03-02Sale

Owner: Forbes, Monica

Title: Chief Financial Officer

Shares: 345,849

Price/Share: $0.59

Value: $204,050.91

Shares Owned: 326,122

Relationship: Officer

Ownership: Direct

2023-03-02Sale

Owner: Ryu, Elly

Title: Principal Accounting Officer

Shares: 17,289

Price/Share: $0.59

Value: $10,200.51

Shares Owned: 148,624

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-10-07	Klichinsky, Michael	Officer	Chief Scientific Officer	Direct	Sale	56,982	0.25	$14,245.50	0	4
2025-10-03	Klichinsky, Michael	Officer	Chief Scientific Officer	Direct	Sale	119,347	0.26	$31,030.22	0	4
2023-03-02	Cannell, Thomas R	Director,Officer	President and CEO	Direct	Sale	487,487	0.59	$287,617.33	344,150	4
2023-03-02	Forbes, Monica	Officer	Chief Financial Officer	Direct	Sale	345,849	0.59	$204,050.91	326,122	4
2023-03-02	Ryu, Elly	Officer	Principal Accounting Officer	Direct	Sale	17,289	0.59	$10,200.51	148,624	4
2023-03-02	Sullivan, Mark	Officer	General Counsel & Secretary	Direct	Sale	219,218	0.59	$129,338.62	198,716	4
2023-03-02	Macdonald, Glen C	Officer	Chief Technology Officer	Direct	Sale	170,372	0.59	$100,519.48	206,751	4
2023-02-21	Ryu, Elly	Officer	Principal Accounting Officer	Direct	Sale	7,159	0.59	$4,223.81	165,913	4
2023-02-21	Cannell, Thomas R	Director,Officer	President and CEO	Direct	Sale	53,727	0.59	$31,698.93	553,073	4
2023-02-21	Macdonald, Glen C	Officer	Chief Technology Officer	Direct	Sale	25,927	0.59	$15,296.93	282,998	4
2023-02-21	Sullivan, Mark	Officer	General Counsel & Secretary	Direct	Sale	39,831	0.59	$23,500.29	299,694	4
2023-02-21	Forbes, Monica	Officer	Chief Financial Officer	Direct	Sale	61,862	0.59	$36,498.58	480,388	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-12-31

3.70%

Inst. Shares: 1,547,384

Shares Outstanding: 41,788,096

2025-09-30

7.26%

Inst. Shares: 3,033,183

Shares Outstanding: 41,788,096

2025-06-30

9.54%

Inst. Shares: 3,986,383

Shares Outstanding: 41,788,096

2025-03-31

12.02%

Inst. Shares: 5,020,379

Shares Outstanding: 41,771,213

2024-12-31

10.35%

Inst. Shares: 4,291,487

Shares Outstanding: 41,456,210

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-12-31	1,547,384	41,788,096	3.70%
2025-09-30	3,033,183	41,788,096	7.26%
2025-06-30	3,986,383	41,788,096	9.54%
2025-03-31	5,020,379	41,771,213	12.02%
2024-12-31	4,291,487	41,456,210	10.35%
2024-09-30	3,415,826	41,588,035	8.21%
2024-06-30	4,854,353	41,543,553	11.68%
2024-03-31	6,968,542	40,938,464	17.02%
2023-12-31	7,435,616	33,524,197	22.18%
2023-09-30	7,203,617	40,285,858	17.88%
2023-06-30	7,285,215	40,258,107	18.10%
2023-03-31	3,223,722	12,783,523	25.22%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Carisma Therapeutics Inc. (CARM) — SEC Financial Statements & Analysis

Carisma Therapeutics Inc. (CARM) is a pharmaceutical preparations company, incorporated in DE. Carisma Therapeutics Inc. trades on OTC as: CARM. Based on its latest SEC filing (Form 10-Q, period ending 2025-09-30), Carisma Therapeutics Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of -8.56x, a Price-to-Sales (P/S) ratio of 16.50x (TTM), a Price-to-Book (P/B) ratio of -13.21x (TTM), at a market cap of $11.45M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: -8.56x
P/S TTM: 16.50x
P/B TTM: -13.21x
Market Cap: $11.45M

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Carisma Therapeutics Inc. in?

Carisma Therapeutics Inc. (CARM) operates in the Pharmaceutical Preparations industry.

What is CARM's market cap?

Carisma Therapeutics Inc. (CARM) has a market capitalization of $11.45M as of 2025-09-30.

What is CARM's P/E ratio?

Carisma Therapeutics Inc. (CARM)'s trailing twelve month P/E ratio is 1.42x as of 2025-09-30.

What exchange does CARM trade on?

Carisma Therapeutics Inc. (CARM) trades on the OTC.

Where is Carisma Therapeutics Inc. incorporated?

Carisma Therapeutics Inc. is incorporated in DE.